LONP1 and plasma cell myeloma: Furthermore, LonP1 showed up to 15-fold differences in expression levels among primary multiple myeloma samples (Figure 2A), indicating that this mitoprotease might contribute to clinically relevant resistance mechanisms or the emergence of relapsed/refractory multiple myeloma.